



AETNA BETTER HEALTH® OF KENTUCKY

Pharmacy & Therapeutics Committee

2020 Third Quarter Meeting

Date: July 28, 2020
Location: WebEx/Call-in Only due to COVID-19
1-844-712-3250 Access Code 717 695 758
Facilitators: Stephanie Whyte, MD, Deputy CMO
April Cox, PharmD, Pharmacy Director

Committee Members			
April Cox, PharmD, Pharmacy Director		Kelly Gannon, Director Clinical Health Services	
Ted Cummings, R.Ph., Sr. Director of Pharmacy		Lauren LaPorta, MD, Medical Director	
Stephanie Whyte, MD, Deputy Chief Medical Officer		Mamata Majmundar, MD, Medical Director	
Avril Anthony-Wilson, MD, Medical Director		LaVeda Gipson, PharmD, PMMP Clinical Pharmacist	
David Chand, MD, Medical Director		Lori Shook, MD, Medical Director	

Meeting Agenda

Topic	Facilitator
Attendance/Introductions (as applicable)	Whyte, S.
April 28, 2020 Meeting Minutes Approval	Cox, A.

Topic	Facilitator
<p>1. New Drug Reviews</p> <p>Quinlock (ripresnib) tab Ziposia 0.92mg cap starter kit Nexlizet (bempedoic acid) 180/10mg tab Palforzia (arac his hypogaea) oral powder Nurtec ODT Tabrecta (Capmatinib) 150mg, 200mg tab Retevmo (selpercatinib) 40, 80mg cap Koselugo (selumetinib) 10, 25mg cap Isturisa (osilodrostat) 5mg, 10mg tab Annovera Mis (segester one acetate 103mg and ethinyl estradiol 17.4mg vaginal system) silicone elastomer Brukinsa (zanubrutinib) 80mg cap</p>	<p>Cox, A.</p>
<p>2. Formulary Changes</p> <p><u>Generics Added in Previous Quarter</u> None</p> <p><u>Generics Not Added in Previous Quarter</u> HM Urinary tab 99.5mg Deferasirox tab 180mg Metformin HCl Sln 500mg/5mL Calcipotriene-Betamethasone Dip Susp 0.005-0.064% Tolvaptan tab 30mg</p> <p><u>New Biosimilars Not Added in Previous Quarter</u> Ontruzant 420mg Avsola 100mg</p>	<p>Cox, A.</p>

3. Drug Class Reviews

No Changes

- Ophthalmic NSAIDs
- Leukotrienes
- Metabolic Modifiers
- Rectal Steroids
- Pulmonary Fibrosis
- Somatostatic Agents
- Anti-Anginals
- Asthma-MoABs
- Chronic ITP Agents
- Platelet Inhibitors
- Antidementia
- Oral Beta Agonists
- Sedative/Hypnotics/Sleep Disorder
- Antimycobacterial
- Potassium Removing Agents
- Ophthalmic Anti-infectives
- Oral Immunosuppresants
- Topical Immunosuppresants
- Diuretics
- CMV
- Potassium
- Glaucoma

With Changes

- Immune Globulin
- Anti-ulcer
- Antianxiety
- GU Alkalinizers
- Cephalosporins
- Macrolides
- Ophthalmic Immunomodulators

With UM Changes Only

- Anaphylaxis agents
- Antiemetics
- Vaginal Anti-Infectives
- Ophthalmic steroids
- Cycloplegic Mydriatics
- Fluoroquinolones

Cox, A.



Topic	Facilitator
4. Formulary Update Summary Valtoco Santyl	Cox, A.
5. Annual Guideline Reviews <u>No Changes</u> Jardiance Nuedexta Ranexa Symlin Synagis Xolair <u>With Changes</u> Compounds Daliresp Diabetic Testing Supplies Divalproex ER Dry Eye Medications High Dose Proton Pump Inhibitors HP Acthar Idiopathic Pulmonary Fibrosis Injectable Osteoporosis Agents Immune Globulins Increlex Interlukin-5 (IL-5) Platelet Inhibitors Progestin only Intrauterine Device Somatostatin Analogs Sucraid Tavalisse Xyrem	Cox, A.



Topic	Facilitator
6. New Guideline Reviews Balversa Duration of Therapy Limits for PPIs Krystexxa Palforzia Reyvow Tepezza Antihistamines Overactive Bladder Topical Corticosteroids	Cox, A.
Adjournment	Whyte, S.
Future Meeting Dates: 4Q2020: October 27, 2020	